Carline N. L. Groenland
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Carline N. L. Groenland has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Diederik Gommers
Department of Intensive Care, Erasmus MC, Rotterdam, Netherlands
3 shared publicationsEvert-Jan Wils
Department of Intensive Care, Franciscus Gasthuis & Vlietland, Rotterdam, Netherlands
3 shared publicationsHenrik Endeman
Department of Intensive Care, Erasmus MC, Rotterdam, Netherlands
3 shared publicationsLeo Heunks
Department of Intensive Care, Radboud University Medical Center, Nijmegen, Netherlands
3 shared publicationsAdinde H. Siemers
Department of Intensive Care, Erasmus MC, Rotterdam, The Netherlands
2 shared publicationsEric A. Dubois
Department of Intensive Care, Erasmus MC, Rotterdam, The Netherlands
2 shared publications
Latest Publications
- 12 February 2026
- Published by European Respiratory Society (ERS)
- Vol. 12 (suppl 17)
Biomarkers during a spontaneous breathing trial to predict extubation failure
Introduction Extubation failure occurs in up to 20%, despite a successful spontaneous breathing trial (SBT). We hypothesized that serial biomarkers during an SBT could identify patients at risk. We aimed to investigate the association between serial biomarkers during an SBT and extubation failure. Methods We included adult patients ventilated ≥48 hours and undergoing an SBT in a multicenter cohort study. Primary and secondary endpoints were extubation failure (reintubation ≤7-days), and ICU mortality. Logistic regression assessed associations between log2-transformed biomarkers at SBT start and their relative change during the SBT with the endpoints. Post-hoc analyses focused on extubation failure due to non-airway failure (exclusion of extubation failure due to airway problems). Results 150 patients were included (mean age 63±13 years, 61% male). None of the biomarkers (start SBT and relative change (not presented)) were associated with extubation failure (n=33, 22%, Figure 1). However, Hs-Troponin-T (Hs-TnT), CKMB, Cystatin-C measured at start of the SBT were associated with extubation failure due to non-airway failure (n=23), and NT-proBNP, Hs-TnT, Galectin-3, and Cystatin-C with ICU mortality. Conclusions Although biomarkers were not associated with extubation failure, we found associations of cardiac and renal biomarkers with non-airway failure (Hs-TnT, CKMB, Cystatin-C) and ICU mortality (NT-proBNP, Hs-TnT, Galectin-3, Cystatin-C). erjor;12/suppl_17/135/F1 F1 F1
- 12 February 2026
- Published by European Respiratory Society (ERS)
- Vol. 12 (suppl 17)
Biomarkers during a spontaneous breathing trial to predict extubation failure
Introduction Extubation failure occurs in up to 20%, despite a successful spontaneous breathing trial (SBT). We hypothesized that serial biomarkers during an SBT could identify patients at risk. We aimed to investigate the association between serial biomarkers during an SBT and extubation failure. Methods We included adult patients ventilated ≥48 hours and undergoing an SBT in a multicenter cohort study. Primary and secondary endpoints were extubation failure (reintubation ≤7-days), and ICU mortality. Logistic regression assessed associations between log2-transformed biomarkers at SBT start and their relative change during the SBT with the endpoints. Post-hoc analyses focused on extubation failure due to non-airway failure (exclusion of extubation failure due to airway problems). Results 150 patients were included (mean age 63±13 years, 61% male). None of the biomarkers (start SBT and relative change (not presented)) were associated with extubation failure (n=33, 22%, Figure 1). However, Hs-Troponin-T (Hs-TnT), CKMB, Cystatin-C measured at start of the SBT were associated with extubation failure due to non-airway failure (n=23), and NT-proBNP, Hs-TnT, Galectin-3, and Cystatin-C with ICU mortality. Conclusions Although biomarkers were not associated with extubation failure, we found associations of cardiac and renal biomarkers with non-airway failure (Hs-TnT, CKMB, Cystatin-C) and ICU mortality (NT-proBNP, Hs-TnT, Galectin-3, Cystatin-C). erjor;12/suppl_17/135/F1 F1 F1
- Open Access
- 12 November 2025
- Published by SAGE Publications in Biomarker Insights
- Vol. 20
The Additional Prognostic Value of Serial Biomarker Measurements for Extubation Failure Among Patients With COVID-19 Acute Respiratory Distress Syndrome
Background: Extubation failure is associated with adverse outcomes in critically ill patients. While single biomarker measurements can aid prediction, repeated biomarker measurements can help to timely recognize underlying diseases. Objectives: The aim of this study was to investigate the temporal evolution of cardiac (N-terminal pro–B-type natriuretic peptide [NT-proBNP], high-sensitivity troponin T [Hs-TnT]) and inflammatory biomarkers (interleukin-6 [IL-6] and procalcitonin [PCT]) prior to extubation and determine their additional prognostic value. Design: Retrospective cohort study. Methods: Patients with COVID-19 extubated after mechanical ventilation were included. Daily biomarker levels were collected up to 3 days before extubation. The primary endpoint was extubation failure, defined as reintubation or death within 7 days. Linear mixed-effect models were used to analyze biomarker trajectories in patients with extubation success and failure. Each day before extubation a logistic regression model (consisting of the 4 biomarkers) was constructed to determine the model with the best discriminative ability. Results: Among 297 patients, 21.5% experienced extubation failure. Log 2 Hs-TnT, NT-proBNP and PCT were higher on all days in patients with extubation failure ( P < .001, P = .01, P = .01, respectively), whereas log 2 IL-6 was not ( P = .54). There was no difference in the change of biomarkers over the days between patients with extubation success and failure ( P -value for interaction = .11, P = .82, P = .31, P = .84, respectively). The performance of the logistic regression model including the 4 biomarkers on the day of extubation was significantly better than the model 3 days before extubation (AUC 0.71, 95% CI: 0.64-0.79 vs AUC 0.66, 95% CI: 0.58-0.73, P = .03). Conclusion: Hs-TnT, NT-proBNP and PCT measured on the days before extubation are consistently higher in patients with extubation failure. However, there was no relation between the change in biomarker levels over time and extubation outcome. The serial assessment of Hs-TnT, NT-proBNP, PCT, and IL-6 do not seem to add prognostic information to predict extubation failure.
- 12 November 2025
- Published by SAGE Publications in Biomarker Insights
- Vol. 20
Open AccessThe Additional Prognostic Value of Serial Biomarker Measurements for Extubation Failure Among Patients With COVID-19 Acute Respiratory Distress Syndrome
Background: Extubation failure is associated with adverse outcomes in critically ill patients. While single biomarker measurements can aid prediction, repeated biomarker measurements can help to timely recognize underlying diseases. Objectives: The aim of this study was to investigate the temporal evolution of cardiac (N-terminal pro–B-type natriuretic peptide [NT-proBNP], high-sensitivity troponin T [Hs-TnT]) and inflammatory biomarkers (interleukin-6 [IL-6] and procalcitonin [PCT]) prior to extubation and determine their additional prognostic value. Design: Retrospective cohort study. Methods: Patients with COVID-19 extubated after mechanical ventilation were included. Daily biomarker levels were collected up to 3 days before extubation. The primary endpoint was extubation failure, defined as reintubation or death within 7 days. Linear mixed-effect models were used to analyze biomarker trajectories in patients with extubation success and failure. Each day before extubation a logistic regression model (consisting of the 4 biomarkers) was constructed to determine the model with the best discriminative ability. Results: Among 297 patients, 21.5% experienced extubation failure. Log 2 Hs-TnT, NT-proBNP and PCT were higher on all days in patients with extubation failure ( P < .001, P = .01, P = .01, respectively), whereas log 2 IL-6 was not ( P = .54). There was no difference in the change of biomarkers over the days between patients with extubation success and failure ( P -value for interaction = .11, P = .82, P = .31, P = .84, respectively). The performance of the logistic regression model including the 4 biomarkers on the day of extubation was significantly better than the model 3 days before extubation (AUC 0.71, 95% CI: 0.64-0.79 vs AUC 0.66, 95% CI: 0.58-0.73, P = .03). Conclusion: Hs-TnT, NT-proBNP and PCT measured on the days before extubation are consistently higher in patients with extubation failure. However, there was no relation between the change in biomarker levels over time and extubation outcome. The serial assessment of Hs-TnT, NT-proBNP, PCT, and IL-6 do not seem to add prognostic information to predict extubation failure.
- Open Access
- 8 January 2025
- Published by Elsevier in Annals of Intensive Care
- Vol. 15 (1) , 1-10
The prognostic role of cardiac and inflammatory biomarkers in extubation failure in patients with COVID-19 acute respiratory distress syndrome
- 8 January 2025
- Published by Elsevier in Annals of Intensive Care
- Vol. 15 (1) , 1-10
Open AccessThe prognostic role of cardiac and inflammatory biomarkers in extubation failure in patients with COVID-19 acute respiratory distress syndrome
- Open Access
- 19 August 2024
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 52 (12) , 1856-1865
Emergency Department Triage, Transfer Times, and Hospital Mortality of Patients Admitted to the ICU: A Retrospective Replication and Continuation Study*
OBJECTIVES: This study aimed to provide new insights into the impact of emergency department (ED) to ICU time on hospital mortality, stratifying patients by academic and nonacademic teaching (NACT) hospitals, and considering Acute Physiology and Chronic Health Evaluation (APACHE)-IV probability and ED-triage scores. DESIGN, SETTING, AND PATIENTS: We conducted a retrospective cohort study (2009–2020) using data from the Dutch National Intensive Care Evaluation registry. Patients directly admitted from the ED to the ICU were included from four academic and eight NACT hospitals. Odds ratios (ORs) for mortality associated with ED-to-ICU time were estimated using multivariable regression, both crude and after adjusting for and stratifying by APACHE-IV probability and ED-triage scores. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: A total of 28,455 patients were included. The median ED-to-ICU time was 1.9 hours (interquartile range, 1.2–3.1 hr). No overall association was observed between ED-to-ICU time and hospital mortality after adjusting for APACHE-IV probability (p = 0.36). For patients with an APACHE-IV probability greater than 55.4% (highest quintile) and an ED-to-ICU time greater than 3.4 hours the adjusted OR (ORsadjApache) was 1.24 (95% CI, 1.00–1.54; p < 0.05) as compared with the reference category (< 1.1 hr). In the academic hospitals, the ORsadjApache for ED-to-ICU times of 1.6–2.3, 2.3–3.4, and greater than 3.4 hours were 1.21 (1.01–1.46), 1.21 (1.00–1.46), and 1.34 (1.10–1.64), respectively. In NACT hospitals, no association was observed (p = 0.07). Subsequently, ORs were adjusted for ED-triage score (ORsadjED). In the academic hospitals the ORsadjED for ED-to-ICU times greater than 3.4 hours was 0.98 (0.81–1.19), no overall association was observed (p = 0.08). In NACT hospitals, all time-ascending quintiles had ORsadjED values of less than 1.0 (p < 0.01). CONCLUSIONS: In patients with the highest APACHE-IV probability at academic hospitals, a prolonged ED-to-ICU time was associated with increased hospital mortality. We found no significant or consistent unfavorable association in lower APACHE-IV probability groups and NACT hospitals. The association between longer ED-to-ICU time and higher mortality was not found after adjustment and stratification for ED-triage score.
- 19 August 2024
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 52 (12) , 1856-1865
Open AccessEmergency Department Triage, Transfer Times, and Hospital Mortality of Patients Admitted to the ICU: A Retrospective Replication and Continuation Study*
OBJECTIVES: This study aimed to provide new insights into the impact of emergency department (ED) to ICU time on hospital mortality, stratifying patients by academic and nonacademic teaching (NACT) hospitals, and considering Acute Physiology and Chronic Health Evaluation (APACHE)-IV probability and ED-triage scores. DESIGN, SETTING, AND PATIENTS: We conducted a retrospective cohort study (2009–2020) using data from the Dutch National Intensive Care Evaluation registry. Patients directly admitted from the ED to the ICU were included from four academic and eight NACT hospitals. Odds ratios (ORs) for mortality associated with ED-to-ICU time were estimated using multivariable regression, both crude and after adjusting for and stratifying by APACHE-IV probability and ED-triage scores. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: A total of 28,455 patients were included. The median ED-to-ICU time was 1.9 hours (interquartile range, 1.2–3.1 hr). No overall association was observed between ED-to-ICU time and hospital mortality after adjusting for APACHE-IV probability (p = 0.36). For patients with an APACHE-IV probability greater than 55.4% (highest quintile) and an ED-to-ICU time greater than 3.4 hours the adjusted OR (ORsadjApache) was 1.24 (95% CI, 1.00–1.54; p < 0.05) as compared with the reference category (< 1.1 hr). In the academic hospitals, the ORsadjApache for ED-to-ICU times of 1.6–2.3, 2.3–3.4, and greater than 3.4 hours were 1.21 (1.01–1.46), 1.21 (1.00–1.46), and 1.34 (1.10–1.64), respectively. In NACT hospitals, no association was observed (p = 0.07). Subsequently, ORs were adjusted for ED-triage score (ORsadjED). In the academic hospitals the ORsadjED for ED-to-ICU times greater than 3.4 hours was 0.98 (0.81–1.19), no overall association was observed (p = 0.08). In NACT hospitals, all time-ascending quintiles had ORsadjED values of less than 1.0 (p < 0.01). CONCLUSIONS: In patients with the highest APACHE-IV probability at academic hospitals, a prolonged ED-to-ICU time was associated with increased hospital mortality. We found no significant or consistent unfavorable association in lower APACHE-IV probability groups and NACT hospitals. The association between longer ED-to-ICU time and higher mortality was not found after adjustment and stratification for ED-triage score.
- Open Access
- 30 May 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (11) , 3242
The Value of Ischemic Cardiac Biomarkers to Predict Spontaneous Breathing Trial or Extubation Failure: A Systematic Review
Background: It is unclear whether other cardiac biomarkers than NT-proBNP can be useful in the risk stratification of patients weaning from mechanical ventilation. The aim of this study is to summarize the role of ischemic cardiac biomarkers in predicting spontaneous breathing trial (SBT) or extubation failure. Methods: We systematically searched Embase, MEDLINE, Web of Science, and Cochrane Central for studies published before January 2024 that reported the association between ischemic cardiac biomarkers and SBT or extubation failure. Data were extracted using a standardized form and methodological assessment was performed using the QUIPS tool. Results: Seven observational studies investigating four ischemic cardiac biomarkers (Troponin-T, Troponin-I, CK-MB, Myoglobin) were included. One study reported a higher peak Troponin-I in patients with extubation failure compared to extubation success (50 ng/L [IQR, 20–215] versus 30 ng/L [IQR, 10–86], p = 0.01). A second study found that Troponin-I measured before the SBT was higher in patients with SBT failure in comparison to patients with SBT success (100 ± 80 ng/L versus 70 ± 130 ng/L, p = 0.03). A third study reported a higher CK-MB measured at the end of the SBT in patients with weaning failure (SBT or extubation failure) in comparison to weaning success (8.77 ± 20.5 ng/mL versus 1.52 ± 1.42 ng/mL, p = 0.047). Troponin-T and Myoglobin as well as Troponin-I and CK-MB measured at other time points were not found to be related to SBT or extubation failure. However, most studies were underpowered and with high risk of bias. Conclusions: The association with SBT or extubation failure is limited for Troponin-I and CK-MB and appears absent for Troponin-T and Myoglobin, but available studies are hampered by significant methodological drawbacks. To more definitively determine the role of ischemic cardiac biomarkers, future studies should prioritize larger sample sizes, including patients at risk of cardiac disease, using stringent SBTs and structured timing of laboratory measurements before and after SBT.
- 30 May 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (11) , 3242
Open AccessThe Value of Ischemic Cardiac Biomarkers to Predict Spontaneous Breathing Trial or Extubation Failure: A Systematic Review
Background: It is unclear whether other cardiac biomarkers than NT-proBNP can be useful in the risk stratification of patients weaning from mechanical ventilation. The aim of this study is to summarize the role of ischemic cardiac biomarkers in predicting spontaneous breathing trial (SBT) or extubation failure. Methods: We systematically searched Embase, MEDLINE, Web of Science, and Cochrane Central for studies published before January 2024 that reported the association between ischemic cardiac biomarkers and SBT or extubation failure. Data were extracted using a standardized form and methodological assessment was performed using the QUIPS tool. Results: Seven observational studies investigating four ischemic cardiac biomarkers (Troponin-T, Troponin-I, CK-MB, Myoglobin) were included. One study reported a higher peak Troponin-I in patients with extubation failure compared to extubation success (50 ng/L [IQR, 20–215] versus 30 ng/L [IQR, 10–86], p = 0.01). A second study found that Troponin-I measured before the SBT was higher in patients with SBT failure in comparison to patients with SBT success (100 ± 80 ng/L versus 70 ± 130 ng/L, p = 0.03). A third study reported a higher CK-MB measured at the end of the SBT in patients with weaning failure (SBT or extubation failure) in comparison to weaning success (8.77 ± 20.5 ng/mL versus 1.52 ± 1.42 ng/mL, p = 0.047). Troponin-T and Myoglobin as well as Troponin-I and CK-MB measured at other time points were not found to be related to SBT or extubation failure. However, most studies were underpowered and with high risk of bias. Conclusions: The association with SBT or extubation failure is limited for Troponin-I and CK-MB and appears absent for Troponin-T and Myoglobin, but available studies are hampered by significant methodological drawbacks. To more definitively determine the role of ischemic cardiac biomarkers, future studies should prioritize larger sample sizes, including patients at risk of cardiac disease, using stringent SBTs and structured timing of laboratory measurements before and after SBT.